Free Trial

Oculis (OCS) News Today

$11.75
0.00 (0.00%)
(As of 06/18/2024 ET)
Oculis logo with Medical background
Oculis Holding AG (NASDAQ:OCS) Short Interest Down 42.2% in May
Oculis Holding AG (NASDAQ:OCS - Get Free Report) was the recipient of a significant decrease in short interest in May. As of May 31st, there was short interest totalling 26,600 shares, a decrease of 42.2% from the May 15th total of 46,000 shares. Approximately 0.1% of the company's stock are short sold. Based on an average trading volume of 37,100 shares, the short-interest ratio is currently 0.7 days.
Oculis' (OCS) Buy Rating Reaffirmed at Chardan Capital
Oculis logo with Medical background
Oculis' (OCS) Buy Rating Reiterated at Chardan Capital
Chardan Capital restated a "buy" rating and set a $30.00 price objective on shares of Oculis in a research note on Tuesday.
Oculis logo with Medical background
HC Wainwright Boosts Oculis (NASDAQ:OCS) Price Target to $30.00
HC Wainwright increased their price objective on shares of Oculis from $28.00 to $30.00 and gave the company a "buy" rating in a report on Tuesday.
Oculis logo with Medical background
Oculis (NASDAQ:OCS) Given New $20.00 Price Target at Bank of America
Bank of America lowered their price objective on shares of Oculis from $21.00 to $20.00 and set a "buy" rating for the company in a research report on Tuesday.
Oculis logo with Medical background
Oculis Holding AG (NASDAQ:OCS) Shares Sold by Pivotal bioVenture Partners Investment Advisor LLC
Pivotal bioVenture Partners Investment Advisor LLC lessened its stake in Oculis Holding AG (NASDAQ:OCS - Free Report) by 14.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,888,788 shares of the company's
Oculis logo with Medical background
Short Interest in Oculis Holding AG (NASDAQ:OCS) Rises By 16.8%
Oculis Holding AG (NASDAQ:OCS - Get Free Report) saw a significant increase in short interest in the month of May. As of May 15th, there was short interest totalling 46,000 shares, an increase of 16.8% from the April 30th total of 39,400 shares. Based on an average trading volume of 39,100 shares, the days-to-cover ratio is currently 1.2 days. Approximately 0.2% of the company's shares are sold short.
Oculis logo with Medical background
Oculis Holding AG (NASDAQ:OCS) Receives Average Recommendation of "Buy" from Brokerages
Oculis Holding AG (NASDAQ:OCS - Get Free Report) has been given a consensus rating of "Buy" by the eight ratings firms that are presently covering the stock, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a buy rating. The average 1 year price target among brokers
Oculis Holding AG (NASDAQ:OCS) to Post Q2 2024 Earnings of ($0.42) Per Share, HC Wainwright Forecasts
Oculis Holding AG (NASDAQ:OCS - Free Report) - Investment analysts at HC Wainwright reduced their Q2 2024 EPS estimates for shares of Oculis in a research report issued to clients and investors on Monday, May 13th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings
Brokers Offer Predictions for Oculis Holding AG's FY2025 Earnings (NASDAQ:OCS)
Oculis Holding AG (NASDAQ:OCS - Free Report) - Equities research analysts at HC Wainwright issued their FY2025 earnings per share estimates for shares of Oculis in a report issued on Monday, May 13th. HC Wainwright analyst Y. Chen expects that the company will earn ($1.62) per share for the year.
Oculis' (OCS) Buy Rating Reaffirmed at HC Wainwright
HC Wainwright reaffirmed a "buy" rating and set a $28.00 price target on shares of Oculis in a research note on Monday.
Oculis (NASDAQ:OCS) Sees Large Volume Increase
Oculis (NASDAQ:OCS) Sees Unusually-High Trading Volume
Oculis (NASDAQ:OCS) Stock Price Up 8.3%
Oculis (NASDAQ:OCS) Shares Up 8.3%
Oculis Holding AG (NASDAQ:OCS) Short Interest Down 21.0% in April
Oculis Holding AG (NASDAQ:OCS - Get Free Report) was the target of a large decline in short interest in April. As of April 15th, there was short interest totalling 25,600 shares, a decline of 21.0% from the March 31st total of 32,400 shares. Based on an average daily volume of 51,100 shares, the short-interest ratio is currently 0.5 days. Currently, 0.1% of the company's stock are sold short.
Oculis Holding AG to Post Q2 2024 Earnings of ($0.37) Per Share, HC Wainwright Forecasts (NASDAQ:OCS)
Oculis Holding AG (NASDAQ:OCS - Free Report) - Equities research analysts at HC Wainwright raised their Q2 2024 earnings estimates for Oculis in a research report issued on Wednesday, April 24th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of ($0.37) per share
abrdn plc Acquires Shares of 1,452,741 Oculis Holding AG (NASDAQ:OCS)
abrdn plc purchased a new stake in Oculis Holding AG (NASDAQ:OCS - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 1,452,741 shares of the company's stock, valued at approximately $15,980,000. abrdn plc owned approximately 3.9
Oculis (NASDAQ:OCS) Price Target Lowered to $28.00 at HC Wainwright
HC Wainwright lowered their price target on Oculis from $29.00 to $28.00 and set a "buy" rating on the stock in a report on Wednesday.
Short Interest in Oculis Holding AG (NASDAQ:OCS) Declines By 31.4%
Oculis Holding AG (NASDAQ:OCS - Get Free Report) was the target of a significant decrease in short interest in March. As of March 31st, there was short interest totalling 32,400 shares, a decrease of 31.4% from the March 15th total of 47,200 shares. Approximately 0.2% of the company's stock are short sold. Based on an average trading volume of 37,700 shares, the short-interest ratio is currently 0.9 days.
Oculis Holding AG (NASDAQ:OCS) Given Average Recommendation of "Buy" by Brokerages
Oculis Holding AG (NASDAQ:OCS - Get Free Report) has received an average rating of "Buy" from the nine ratings firms that are covering the firm, Marketbeat Ratings reports. Nine investment analysts have rated the stock with a buy recommendation. The average 1 year price objective among analysts th
Leerink Partnrs Comments on Oculis Holding AG's Q1 2024 Earnings (NASDAQ:OCS)
Oculis Holding AG (NASDAQ:OCS - Free Report) - Equities research analysts at Leerink Partnrs issued their Q1 2024 earnings per share estimates for shares of Oculis in a research note issued on Wednesday, March 20th. Leerink Partnrs analyst M. Goodman forecasts that the company will post earnings
Get Oculis News Delivered to You Automatically

Sign up to receive the latest news and ratings for OCS and its competitors with MarketBeat's FREE daily newsletter.

Elon’s New Device is About to Shock the World (Ad)

Using this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.”

Click here to see the details because there’s a lot of money at stake.

OCS Media Mentions By Week

OCS Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

OCS
News Sentiment

0.58

0.90

Average
Medical
News Sentiment

OCS News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

OCS Articles
This Week

5

2

OCS Articles
Average Week

Get Oculis News Delivered to You Automatically

Sign up to receive the latest news and ratings for OCS and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:OCS) was last updated on 6/18/2024 by MarketBeat.com Staff

From Our Partners